LG-2527
From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
| Clinical data | |
|---|---|
| Drug class | Progestin; Progestogen |
LG-2527 is a nonsteroidal progestin which was under development by Ligand Pharmaceuticals and Wyeth for the treatment of menopausal symptoms and breast cancer, but was never marketed.[1] It reached the preclinical stage of development prior to the discontinuation of its development in early 2001.[1]
References
[edit]- ^ a b "LG 2527 - AdisInsight". adisinsight.springer.com.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=LG-2527&oldid=1239044753"
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Short description is different from Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All stub articles